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 30 
Key points 31 
Question: Does monthly high-dose vitamin D supplementation prevent cancer? 32 
 33 
Findings: In a randomized clinical trial that included 5108 participants from the community, the 34 
cumulative incidence of cancer over a median follow-up period of 3.3 years was 6.5% in 35 
participants given 100,000 IU monthly doses of vitamin D3 and 6.4% in those given placebo.  36 
 37 
Meaning: Monthly high-dose vitamin D supplementation did not prevent cancer and should not 38 
be used for this purpose.  39 
  40 
4 
 
Abstract 41 
Importance: Previous randomized controlled trials have provided inconsistent results on the 42 
effect of vitamin D supplementation on cancer incidence. 43 
Objective: To determine if monthly high-dose vitamin D supplementation, without calcium, 44 
reduces cancer incidence and cancer mortality in the general population.  45 
Design: Randomized, double-blind, placebo-controlled trial, participants recruited from April 46 
2011 to November 2012, follow-up until December 2015. 47 
Setting: Recruited mostly from family practices in Auckland, New Zealand. 48 
Participants: Community-resident adults, aged 50-84 years. Out of 47,905 adults invited from 49 
family practices, and 163 from community groups, 5,110 participants were randomized to 50 
vitamin D3 (n=2,558) or placebo (n=2,552). Two participants withdrew consent, and all others 51 
(n=5,108) were included in the primary analysis. 52 
Intervention: Oral vitamin D3, initial bolus dose of 200,000 IU, followed one month later by 53 
monthly doses of 100,000 IU, or placebo, for median of 3.3 years (range: 2.5–4.2 years).  54 
Main Outcomes and Measures:  The post-hoc primary outcome was all primary neoplasms 55 
(invasive and in-situ), aside from non-melanoma skin cancers, diagnosed from randomization to 56 
stopping the study medication (31 July 2015). Secondary outcomes were all neoplasms: from 57 
randomization to 31 December 2015; from >12 months after randomization to both stopping 58 
the study medication and also to 31 December 2015; and fatal neoplasms from randomization 59 
to 31 December 2015.  60 
Results: Mean (SD) age was 65.9 (8.3) years, 58% were male, and 83% were white, with the 61 
remainder being Polynesian or South Asian. Mean (SD) baseline deseasonalized 25(OH)D 62 
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concentration was 26.5 (9.0) ng/mL. In a random sample of 438 participants, mean follow-up 63 
25(OH)D was consistently >20 ng/mL higher in the vitamin D supplemented than placebo group. 64 
The primary cancer outcome comprised 328 total cancer cases (259 invasive, 69 in situ); and 65 
occurred in 6.5% of the vitamin D group and 6.4% of the placebo group, giving an adjusted 66 
hazard ratio of 1.01 (95%CI, 0.81–1.25). Similar results were seen for all secondary outcomes, 67 
including cancer mortality. 68 
Conclusions and Relevance: Monthly high-dose vitamin D supplementation for up to 4 years, 69 
without calcium, does not prevent cancer. Further study is required on the effect of daily or 70 
weekly dosing for longer duration.  71 
 72 
Trial Registration: Australian New Zealand Clinical Trials Registry, Identifier 73 
ACTRN12611000402943, 74 
(https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=336777) 75 
 76 
  77 
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 78 
The hypothesis that vitamin D may protect against cancer arose from ecological studies, 79 
published since the 1980s, that reported inverse associations between sun exposure, the major 80 
source of vitamin D, and incidence of several types of cancer.1-4  Subsequent meta-analyses of 81 
cohort studies have provided further evidence, with low baseline 25-hydroxyvitamin D 82 
(25(OH)D) concentrations predicting increased cancer risk during follow-up, particularly of 83 
colorectal cancer.5-7  In contrast, the recent evidence from Mendelian randomization studies is 84 
inconsistent, with genetically low 25(OH)D concentrations associated with increased risk of 85 
cancer mortality and ovarian cancer in two studies,8,9  but not with several types of cancer in a 86 
third.10  87 
Randomized controlled trials (RCT) of vitamin D supplementation have also provided 88 
inconsistent results. The Women’s Health Initiative did not show a protective effect of daily 89 
vitamin D and calcium supplementation against incidence of colorectal, breast and all invasive 90 
cancer, which could have been due to the low vitamin D dose (400 IU/day).11-13  In contrast, two 91 
subsequent trials by one research group, which gave a higher vitamin D dose (2000 IU/day) 92 
with calcium, reported a reduced incidence of all types of cancer in the treatment arm.14,15  A 93 
consistent finding in both studies was a ~1-year lag from randomization for the vitamin D 94 
benefit to appear on survival curves, although this analysis was not pre-specified.  95 
Given the limited trial evidence on vitamin D supplementation and cancer, we carried 96 
out a post-hoc analysis of a large community-based RCT to determine if vitamin D 97 
supplementation prevents cancer,  in a trial where the original primary aim was to assess the 98 
effect of vitamin D supplementation on cardiovascular disease incidence.16  We also included 99 
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cancer mortality as a secondary outcome, given evidence from a recent meta-analysis  100 
suggesting  that vitamin D supplements reduce cancer mortality, but not cancer incidence.17  101 
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Methods 102 
Study Design 103 
The Vitamin D Assessment (ViDA) study is a randomized, double-blind, placebo-controlled 104 
trial carried out in Auckland, New Zealand, during 2011-2015. Full details of the study methods 105 
have been published.18  Inclusion criteria were: age 50–84 years; ability to give informed 106 
consent; resident in Auckland at recruitment; and anticipated residence in New Zealand for the 107 
4-year study period. Exclusion criteria were: current use of vitamin D supplements, including 108 
cod-liver oil (>600 IU/day if aged 50–70 years; >800 IU/day if aged 71–84 years);19 diagnosis of 109 
psychiatric disorders that would limit ability to comply with study protocol; history of 110 
hypercalcemia, nephrolithiasis, sarcoidosis, parathyroid disease or gastric bypass surgery; 111 
enrolment in another study that could affect participation; or baseline serum-corrected calcium 112 
>10.0 mg/dL.  The Multi-region Ethics Committee (MEC/09/08/082) approved the study, which 113 
was registered with the Australian New Zealand Clinical Trials Registry 114 
(ACTRN12611000402943).  115 
Participant Recruitment and Baseline Assessment 116 
Participants were recruited mainly from 55 family practices in Auckland; 94% of New 117 
Zealand population is registered with family practices.20   Starting March 2011, a personalized 118 
letter was mailed to the homes of potential participants (n=47,905) inviting them to participate; 119 
Out of 8,688 who replied, 5,107 were interested and eligible for baseline assessments. An 120 
additional 163 potential participants from ethnic minority community groups were screened, 121 
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and 143 were eligible. Altogether, 5,250 had a baseline assessment from 5 April 2011 to 6 122 
November 2012 (Figure 1).  123 
The baseline assessment included collecting written informed consent, followed by 124 
questions on: socio-demographic status; lifestyle (tobacco smoking, alcohol drinking over the 125 
last 12 months, and usual leisure-time physical activity21  and sun exposure22  over the last 126 
three months); intake of vitamin D or calcium supplements; and past medical history told by a 127 
doctor (including cancer and age of cancer diagnosis). We measured height (±0.1 cm) and 128 
weight (±0.1 kg) in light clothing without shoes. A non-fasting blood sample was collected to 129 
screen for hypercalcemia, with the remaining serum aliquoted and stored at -80°C for later 130 
25(OH)D measurement.  131 
Randomization 132 
After the baseline assessment, participants were mailed a ‘run-in’ questionnaire with a 133 
blinded placebo capsule, and were included if they returned the questionnaire within 4 weeks, 134 
confirmed in the questionnaire they took the capsule, and did not have hypercalcemia 135 
(corrected calcium ≤10.0 mg/dL). A total of 5,110 participants (4,972 from practices, 138 from 136 
community) were randomized from 03 June 2011 to 23 January 2013 into one of the two 137 
treatment groups, within random blocks of 8, 10 or 12, within ethnic group and 5-year age 138 
strata. Treatment was allocated using computer generation by the study biostatistician; all 139 
other staff and participants were blinded.  140 
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Intervention 141 
Vitamin D3 (2.5 mg or 100,000 IU) or placebo softgel oral capsules, sourced from Tishcon 142 
Corporation (Westbury, NY), were mailed to participants’ homes, with a 1-page questionnaire 143 
(and reply-paid envelope) to record self-reported adherence; the return of which was used to 144 
monitor retention.  Two capsules were sent in the first mail-out post-randomization (i.e., 145 
200,000 IU bolus, or placebo), followed one month later (and thereafter monthly) with 100,000 146 
IU  vitamin D3 or placebo capsules.  A monthly 100,000 IU vitamin D dose was chosen as 147 
pharmacokinetic research showed this dose maintained serum 25(OH)D levels >35 ng/mL for a 148 
month post-ingestion.23  The aim was to raise serum 25(OH)D throughout the year to 32-40 149 
ng/mL, which observational studies then suggested was optimal for health.24-27   150 
Capsules continued to be mailed monthly until June 2013. For cost reasons, from July 151 
2013 onward, four capsules were mailed every four months, with monthly email/letter 152 
reminders to participants to take their monthly capsule. Questionnaires were mailed monthly 153 
until November 2013, and then from March 2014 onward were sent 4-monthly with the four 154 
capsules. Participants stopped their assigned study medication on 31 July 2015. 155 
Serum Calcium and 25-Hydroxyvitamin D 156 
Serum-corrected calcium was measured at baseline on an Advia 2400 analyser (Siemens 157 
Healthcare Diagnostics, Eschborn, Germany). Serum 25(OH)D, combining D2 and D3, was 158 
measured in baseline aliquots stored frozen at −80°C (−112°F) by liquid chromatography–159 
tandem mass spectrometry (ABSciex API 4000, Framingham, MA) with 12.7% inter-assay 160 
coefficient of variation in a local laboratory participating in the Vitamin D External Quality 161 
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Assessment Scheme program (www.deqas.org).  In a 10% random sample, 438 (85% of 515 162 
invited) participants agreed to return at 6, 12, 24 and 36 months for collection of further blood 163 
samples to measure corrected calcium (on fresh blood) and 25(OH)D (on stored blood, 164 
measured in the same batch for each participant). Season-adjusted (deseasonalized) 25(OH)D 165 
values were calculated for each participant from their individual baseline 25(OH)D 166 
concentration and blood collection date, using a sinusoidal model with parameters derived 167 
from baseline values for all participants.28  Vitamin D deficiency was defined as a 168 
deseasonalized 25(OH)D <20 ng/mL.28 169 
Cancer Outcomes 170 
The New Zealand Ministry of Health maintains registries of all primary neoplasms (invasive 171 
and in-situ) diagnosed (from pathology reports including cancer site and morphology) in New 172 
Zealand, excluding non-melanoma skin cancers, and of all deaths.29  The accuracy of the cancer 173 
registry is similar to clinical audits of cancer registries in the US and Europe.30 174 
All New Zealand residents are assigned a unique Ministry of Health National Health Index 175 
(NHI) number. These were collected from all study participants, who gave their consent for the 176 
study researchers to access their Ministry of Health data. The NHI numbers were used to link 177 
individuals with cancer registration data and deaths. Information collected about cancer history 178 
at the baseline assessment was used to help distinguish between prevalent and incident cases 179 
in the Cancer Registry data.  180 
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The aim of our analysis was to replicate (as much as possible) the outcome definitions and 181 
statistical analysis methods used by Lappe and colleagues.15  Cancer cases were defined as ICD-182 
10 codes C00-D09, or cancer deaths.  183 
The primary outcome was time to first cancer reported for all neoplasms (defined above), 184 
from randomization to stopping the study medication (31 July 2015). The primary outcome was 185 
examined in the following pre-specified groups: overall (all participants); by sex and by baseline 186 
deseasonalized 25(OH)D level (<20 ng/mL, ≥ 20 ng/mL). 187 
The secondary outcomes were all neoplasms (defined above): reported from >12 months 188 
post-randomization to stopping the study medication (31 July 2015), from randomization to 31 189 
December 2015, from one year post-randomization to 31 December 2015; and cancer deaths 190 
post-randomization to 31 December 2015. Each secondary outcome was examined in the pre-191 
specified groups described above for the primary outcome. The follow-up period for some 192 
secondary outcomes continued for 5 months after stopping supplementation (to 31 December 193 
2015), as serum 25(OH)D remains higher in vitamin D-supplemented people than those on 194 
placebo for up to a year after stopping supplementation.31   195 
The study protocol specified identifying new cancer cases, to later combine data for 196 
common cancers with cancer data from other vitamin D supplementation trials, but not as an 197 
outcome for the ViDA study. As this report is a post-hoc analysis of data collected for other 198 
outcomes, we developed the statistical analysis plan for the cancer outcomes (Online 199 
Supplement), and registered cancer as a secondary outcome with the trial website on 10 200 
October 2017, before receiving the Ministry of Health cancer data on 08 November 2017. 201 
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Statistical Analysis 202 
Analysis of the cancer outcomes was conducted on an intention-to-treat basis, using NHI 203 
numbers to identify cancer registrations and deaths, regardless of whether participants 204 
continued to participate actively in the study by returning home questionnaires.  Cox regression 205 
proportional hazards models, with robust sandwich variance estimates were used to compare 206 
time to first cancer in the two treatment groups. Non-cancer deaths were censored. Analyses 207 
were performed using SAS version 9.4 (SAS Institute, Cary, NC), and p-value <0.05 (two-sided) 208 
was considered significant. Weighted Schoenfeld residuals were used to check the proportional 209 
hazards assumption which was not violated for any variable in the model – treatment, age, sex 210 
and ethnicity (all p>0.05). Based on an overall cumulative incidence of 6.4% (328 cancer cases 211 
for primary outcome), the study had 85% power to detect a risk ratio of 0.70 with 2-sided 95% 212 
confidence interval (www.openepi.com/Power/PowerRCT.htm). 213 
214 
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RESULTS 215 
Recruitment and Baseline Characteristics 216 
From 8,851 participants assessed for eligibility, 5,250 had baseline assessments, and 217 
5,110 were randomized. We later excluded two individuals who withdrew consent post-218 
randomization for their data to be retained by the researchers, so 5,108 were included in the 219 
analysis of the primary outcome (Figure 1). Overall, 58% of participants were male, 83% were of 220 
“other” ethnicity (96% of whom had European ancestry). At baseline: mean (SD) age was 65.9 221 
(8.3) years; only 6% currently smoked tobacco while 43% were ex-smokers; 24% reported being 222 
told by a doctor previously of having had cancer; mean (SD) observed 25(OH)D was 25.3 (9.5) 223 
ng/mL and deseasonalized was 26.5 (9.0) ng/mL. Baseline characteristics were similar between 224 
vitamin D and placebo groups (Table 1).  225 
Follow-up and Adherence 226 
Figure 1 shows the flow diagram of follow-up after randomization. Fifteen deaths 227 
occurred within one year post-randomization, a further 108 by the end of the active follow-up 228 
period (31 July 2015), and a further 32 by the end of passive follow-up (31 December 2015). 229 
This yielded a total of 155 deaths (75 in vitamin D group, 80 in placebo group) for the total 230 
follow-up period. 231 
The majority (98%) of participants confirmed by questionnaire, within 2 months post-232 
randomization, that they had started taking the study capsule, and only 21 (1%) of the vitamin 233 
D group and 49 (2%) of the placebo group never confirmed this during the active follow-up 234 
period from randomization to 31 July 2015 (median 3.3 years; range 2.5 to 4.2 years). During 235 
the last five months of active follow-up, 87% of participants were actively involved in the trial, 236 
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as indicated by the 4,032 (81%) who returned the final July 2015 questionnaire and a further 237 
283 (6%) who returned the penultimate March 2015 questionnaire.  238 
Adherence to taking the study capsule reported in the home questionnaires was 85% in 239 
the vitamin D group and 83% in the placebo (84% overall, 168,667 capsules reported taken 240 
during 200,936 person-months) up to 31 July 2015. This high adherence was confirmed by the 241 
mean observed 25(OH)D concentrations of the randomly-selected participants who returned to 242 
give blood samples at 6 months, and up to 36 months post-randomization, which ranged from 243 
48 to 54 ng/mL in the vitamin D group, being consistently >20 ng/mL higher than the mean in 244 
the placebo group (Figure e1 in Supplement). Mean (SD) serum calcium levels throughout the 245 
follow-up period in this sub-sample were similar for the vitamin D vs placebo groups, being 246 
respectively, 9.2 (0.4) vs 9.2 (0.4) mg/dL at 6, 12 and 24 months, and 9.6 (0.4) vs 9.6 (0.4) mg/dL 247 
at 36 months. No participants in this sub-sample developed hypercalcemia related to taking the 248 
study capsules.  249 
Cancer Outcomes 250 
There were 375 participants who had a first cancer registration post-randomization (60 of 251 
whom died) and another 29 who died from cancer diagnosed before randomization, giving a 252 
total of 404 participants with a cancer outcome up to 31 December 2015. The types of cancer 253 
are shown in Table 2. The most common cancer was melanoma-in-situ (n=71) and malignant 254 
melanoma (n=55), followed by prostate cancer (n=64), colorectal (n=38), breast (n=36) and 255 
lymphoid and hematopoietic cancers (n=36). 256 
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The numbers of participants with the primary and secondary outcomes during follow-up in 257 
the vitamin D and placebo groups, along with hazard ratios (HR) adjusted for age, sex, and 258 
ethnicity, are shown in Table 3. There was no difference in the percentage of participants with 259 
cancer registrations from randomization to 31 July 2015 (primary endpoint) between vitamin D 260 
(6.5%) and placebo (6.4%) arms (HR 1.01; 95% CI, 0.81–1.25). Similar results were seen in men 261 
(HR 0.96; 95% CI, 0.74–1.25) and women (HR 1.09; 95% CI, 0.75–1.59; P interaction = 0.57), and in 262 
participants with 25(OH)D <20 ng/ml (HR 1.01; 95% CI, 0.65–1.58) and ≥20 ng/mL (HR 1.04; 95% 263 
CI, 0.81–1.33; P interaction = 0.80). There was no difference between vitamin D and placebo arms 264 
in the time to first cancer registration up to 31 July 2015, including from one year post-265 
randomization (Figure 2). Similar results were seen for all secondary outcomes, as well as for 266 
non-skin cancers (Table 3). Stratifying the sample by sex and baseline 25(OH)D concentration 267 
produced similar results for all secondary outcomes (Table e1 in Supplement).  268 
17 
 
DISCUSSION 269 
The results of this large RCT show that monthly high-dose vitamin D supplementation did 270 
not prevent incident cancer nor reduce cancer mortality in people selected from the 271 
community. The cancer incidence results are consistent with findings from previous RCTs of 272 
community samples in the US and Britain which reported hazard ratios of 0.98 (P=0.54) and 273 
1.09 (P=0.47), respectively,13,32 and with a recent meta-analysis of vitamin D supplementation 274 
trials.17  However, our results in Table 3 comparing the vitamin D and placebo group do not 275 
confirm results of borderline statistical significance from a recent Nebraska study reporting a 276 
35% reduced hazard ratio for follow-up starting from 12 months after randomization (P=0.047), 277 
nor the 30% reduced hazard ratio for follow-up starting from randomization (P=0.06).15   278 
Neither do our results confirm a recent meta-analysis of three trials which found that vitamin D 279 
supplementation significantly reduced cancer mortality by 12%.17  280 
 There are several possible explanations for why our trial did not observe a similar 281 
reduction in cancer incidence from vitamin D as the recent Nebraska study.15  First, we gave 282 
bolus dosing rather than daily dosing of vitamin D. Recent studies suggest that vitamin D is 283 
more able to enter cells than 25(OH)D for conversion to the active metabolite of vitamin D,33  284 
and in our study vitamin D would only have been present in the blood circulation for several 285 
days after each monthly dose because of its short half-life.34 Thus, the Nebraska study may 286 
have produced a stronger continuous vitamin D exposure from their daily dose. Second, we 287 
gave vitamin D by itself rather than with calcium. It is possible the effect of both together, 288 
acting separately or synergistically, is more effective than vitamin D alone, although a reduction 289 
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in cancer incidence was not seen in the Women’s Health Initiative which also gave both 290 
supplements together.13.  Third, the cancer profile in the ViDA study had a much greater 291 
proportion of cases with melanoma (33%, Table 2) compared to the Nebraska study (6%), 292 
although analyses restricted to non-skin cancer produced a similar null result. The similar 293 
results for men and women in our study (Table 3) suggests that the inclusion of only women in 294 
the Nebraska study is an unlikely explanation for the difference in the results between our two 295 
studies.  296 
Other possible reasons for the null result in our study include insufficient participants (25%) 297 
with vitamin D deficiency, which limited statistical power in that subgroup. However, the lower 298 
mean baseline observed 25(OH)D concentration in the ViDA study compared with the Nebraska 299 
study (25.3 versus 32.8 ng/mL) suggests that participants in the former were more likely to be 300 
vitamin D-deficient. Another possible explanation for the null finding is the relatively short 301 
follow-up time (median 3.3 years) which may have been too short to detect any effect of 302 
vitamin D supplementation against cancer. 303 
Our study has important strengths. As our sample was recruited from the community, 304 
results are likely to be relevant for the general population. Adherence to the study capsule was 305 
high, as confirmed by the doubling in mean 25(OH)D concentration vitamin D arm of the 306 
random sub-sample (Supplementary Figure), which was 54.1 ng/mL at 36 months follow-up in 307 
the vitamin D arm, 9 ng/mL higher than in the Nebraska study.  Retention and active 308 
participation in the study were high: 87% returned the final two questionnaires. We enquired 309 
extensively at the baseline assessment about cancer history, which allowed us to identify 310 
cancer cases incident after randomization; and these were systematically identified from the 311 
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cancer registry, regardless of whether participants continued to actively participate, allowing us 312 
to do intention-to-treat analyses. While our study had 85% power to detect a risk ratio of 0.70, 313 
observed in the Nebraska study,15  our power was much lower for detecting weaker effects 314 
against cancer from vitamin D, including the modest 12% reduction in cancer mortality 315 
reported in a recent meta-analysis of vitamin D supplementation.17 316 
In conclusion, we showed that monthly high-dose vitamin D supplementation, for up to 4 317 
years, without calcium, did not prevent cancer. Further research is required on the effects of 318 
daily or weekly dosing of vitamin D on cancer risk for longer durations.   319 
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Legend for Figures 350 
Figure 1:  Flow diagram for the cancer outcome in the ViDA study.  351 
 352 
Figure 2: Proportion (95% CI) of participants developing cancer during follow-up to 31 July 353 
2015, by study group.  354 
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Table 1: Baseline comparison of the vitamin D supplemented and placebo groups 452 
 453 
Variable Vitamin D 
(n=2,558) 
Placebo 
(n=2,550) 
Age (years), No. (%)   
  50-59 571 (22.3) 567 (22.2) 
  60-69 1112 (43.5) 1108 (43.5) 
  70-79 716 (28.0) 722 (28.3) 
  80-84 159 (6.2) 153 (6.0) 
Sex – male, No. (%) 1512 (59.1) 1457 (57.1) 
Ethnicity %   
  Maori 137 (5.4) 135 (5.3) 
  Pacific Islander 168 (6.6) 166 (6.5) 
  South Asian 126 (4.9) 123 (4.8) 
  European / Other 2127 (83.2) 2126 (83.4) 
Education (highest level), No. (%)a   
  Primary school 53 (2.1) 42 (1.6) 
  Secondary school 1091 (42.7) 1036 (40.6) 
  Tertiary 1412 (55.2) 1470 (57.7) 
In paid employment, No. (%) a   
  Yes 1301 (50.9) 1317 (51.6) 
  No   
    Retired 1041 (40.7) 1018 (39.9) 
    Other 211 (8.2) 212 (8.3) 
Tobacco smoking, No. (%) a   
  Current 164 (6.4) 156 (6.1) 
  Ex 1101 (43.0) 1072 (42.0) 
  Never 1286 (50.3) 1317 (51.6) 
Alcohol drinking, No. (%) a   
  Current 2177 (85.1) 2211 (86.7) 
  Ex 224 (8.8) 183 (7.2) 
  Never 151 (5.9) 154 (6.0) 
Vigorous physical activity (hours per week), 
No. (%) 
  
  None 1015 (39.7) 1018 (39.9) 
  1-2 609 (23.8) 585 (22.9) 
  >2 804 (31.4) 832 (32.6) 
  Refused/Don’t know 130 (5.1) 115 (4.5) 
Anthropometry, mean (SD)   
  Weight, kg 81.3 (16.5) 81.2 (16.0) 
  Body mass index, kg/m2 28.4 (5.1) 28.5 (5.1) 
27 
 
Sun exposure (hours per day), No. (%) a   
  <1 350 (13.7) 369 (14.5) 
  1-2 1562 (61.1) 1559 (61.1) 
  >2 611 (23.9) 588 (23.1) 
Take supplements, No. (%)   
  Vitamin D b 208 (8.1) 200 (7.8) 
  Calcium 125 (4.9) 127 (5.0) 
Previous cancer told by a doctor, No. (%)   
  Yes (all cancers) 622 (24.4) 592 (23.3) 
  Lung cancer 35 (1.4) 41 (1.6) 
  Breast cancer (women) 56 (5.4) 54 (5.0) 
  Prostate cancer (men) 94 (6.3) 84 (5.8) 
  Melanoma 107 (4.2) 101 (4.0) 
  Non-melanoma skin cancer 289 (11.4) 295 (11.6) 
  Other 41 (1.6) 17 (0.7) 
Corrected serum calcium, mean (SD), mg/dL 9.2 (0.4) 9.2 (0.4) 
25-hydroxyvitamin D   
  Observed, mean (SD), ng/mLc 25.5 (9.5) 25.2 (9.4) 
  <20 ng/mL, observed, No. (%) 746 (29.2) 788 (30.9) 
  <20 ng/mL, deseasonalized, No. (%) 612 (23.9) 658 (25.8) 
 454 
a percent do not add to 100.0% because of missing/don’t know responses. 455 
b ≤600 IU per day if aged 50-70 years; ≤800 IU per day if aged 71-84 years. 456 
c conversion to SI units: 1 ng/mL = 2.496 nmol/L  457 
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Table 2:  Number of cancer registrations and deaths during follow-up to 31 December 2015, by type of cancer. 458 
 459 
 Alive at 
31 December 2015 
Deaths  
Total 
Type of cancer First cancer registration 
AFTER randomisation 
Cancer registration 
AFTER randomisation 
Cancer registration 
BEFORE randomisation 
Invasive neoplasms 
Colorectal 28 8 2 38 
Oropharynx & Other digestive tract 17 11 3 31 
Respiratory & Intrathoracic organs 9 12 0 21 
Malignant melanoma & Other 
malignant neoplasm of skin 
50 1 4 55 
Breast 31 2 3 36 
Prostate  56 1 7 64 
Lymphoid & Hematopoietic 25 8 3 36 
Other  17 17 7 41 
In situ neoplasms 
Melanoma in situ 71 0 0 71 
Other carcinoma in situ 11 0 0 11 
Total 315 60 29 404 
 460 
 461 
 462 
 463 
 464 
  465 
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Table 3:  Proportion of participants having incident cancer (C00-D09), or dying from cancer, during follow-up, and hazard ratios (placebo 466 
as reference) adjusting for age, sex (as appropriate), and ethnicity, by study treatment group. 467 
Cancer outcome Vitamin D 
(n=2,558) 
Placebo 
(n=2,550) 
Adjusted Hazard 
Ratio (95% CI) 
P-value 
(Wald X2) 
 N of events (%) N of events (%)   
Primary outcome: cancer registration from randomization to 31 July 2015  
    All participants a 165 (6.5) 163 (6.4) 1.01 (0.81, 1.25) 0.95 
    Males 108 (7.2) 110 (7.6) 0.96 (0.74, 1.25) 0.76 
    Females 57 (5.5) 53 (4.9) 1.09 (0.75, 1.59) 0.66 
    25(OH)D <20 ng/mLb 37 (6.0) 42 (6.4) 1.01 (0.65, 1.58) 0.96 
    25(OH)D ≥20 ng/mL c 128 (6.6) 121 (6.4) 1.04 (0.81, 1.33) 0.79 
Secondary outcomes for all participants 
    Cancer registration: randomization to 31 December 2015 188 (7.4) 187 (7.3) 1.00 (0.82, 1.22) 0.99 
    Cancer deaths: randomization to 31 December 2015     
             Cancer registration after randomization d 30 (1.2) 30 (1.2) 0.99 (0.60, 1.64) 0.97 
             All cancer deaths e 44 (1.7) 45 (1.8) 0.97 (0.64, 1.47) 0.89 
    Cancer registration: one year after randomization to: f     
             31 July 2015 116 (4.6) 122 (4.9) 0.95 (0.74, 1.23) 0.69 
             31 December 2015 139 (5.6) 146 (5.8) 0.95 (0.75, 1.19) 0.64 
    Non-skin cancer registration: randomization to 31 July 2015 g 111 (4.4) 111 (4.5) 0.99 (0.76, 1.29) 0.96 
    Invasive cancer registration: randomization to 31 July 2015 h 128 (5.1) 131 (5.2) 0.97 (0.76, 1.24) 0.80 
a Includes 58 deaths due to cancer (28 in vitamin group and 30 in placebo group) 468 
b Based on deseasonalized concentrations – denominator: vitamin D = 612 participants, placebo= 658. 469 
c Denominator: vitamin D = 1946, placebo = 1892. 470 
d Denominator: vitamin D = 2544, placebo = 2535. Excludes those who died from cancer that was diagnosed before randomization. 471 
e Includes 29 deaths from cancer diagnosed before randomization (14 in vitamin D group and 15 in placebo group). 472 
f Denominator: vitamin D = 2504, placebo = 2504. Excludes those who were registered with cancer within 12 months of randomization. 473 
30 
 
g Excludes malignant melanoma, other malignant neoplasm of skin and melanoma in situ. 474 
h Excludes in situ neoplasms. 475 
  476 
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Figure 2:  Proportion (95% CI) of participants developing cancer during follow-up to 31 July 2015, by study group. 479 
 480 
 481 
Number at risk 0 1 year 2 years 3 years 4 years 
Vitamin D 2558 2504 2453 1760 374 
Placebo 2550 2504 2447 1899 275 
 482 
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By 1 year after randomization
6 Died (1 with cancer)
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